Mirabegron + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Overactive Bladder (OAB)
Conditions
Overactive Bladder (OAB)
Trial Timeline
Oct 7, 2014 → Jan 2, 2018
NCT ID
NCT02216214About Mirabegron + Placebo
Mirabegron + Placebo is a approved stage product being developed by Astellas Pharma for Overactive Bladder (OAB). The current trial status is completed. This product is registered under clinical trial identifier NCT02216214. Target conditions include Overactive Bladder (OAB).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04641975 | Phase 3 | Terminated |
| NCT02787083 | Phase 3 | Terminated |
| NCT02216214 | Approved | Completed |
| NCT02086188 | Approved | Completed |
| NCT02092181 | Approved | Completed |
| NCT01284309 | Phase 1 | Completed |
| NCT00912964 | Phase 3 | Completed |
| NCT00662909 | Phase 3 | Completed |
| NCT00410514 | Phase 2 | Completed |
Competing Products
20 competing products in Overactive Bladder (OAB)